An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advanced Refractory Cancer
1. To measure the time from biopsy to completion and final analysis of Whole Genome
Sequencing (WGS) on patient tumor and non-tumor samples.
2. To examine the frequency with which useable sequence data is obtained as a function of
tumor volume received and percent tumor involvement in the biopsy
3. To identify the frequency with which potential targets and pathways for therapy are
4. To observe for any evidence that if anti-tumor activity from treatment is noted how
would the genome sequencing have correlated with that activity.
Glen J Weiss, M.D.
United States: Institutional Review Board
|Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare||Scottsdale, Arizona 85258|